Table 4.

Significant correlations between overall survival (OS) and progression-free survival (PFS) after CART-133 cell treatment in advanced HCC patients with pretreatment and on-treatment changes (normalized to baseline values) in biomarkers (in bold text)

Biomarker/timepoint	Pretreatment Baseline OS	PFS	On-treatment D 7 OS	PFS	D 14 OS	PFS
VEGF	0.142(0.022–0.911)	0.013(0.001–0.192)	1.355(0.995–1.845)	1.838(1.205–2.804)	1.111(0.911–1.354)	1.126(0.95–1.333)
P value	0.004	0.001	0.054	0.005	0.298	0.17
sVEGFR2	0.005(0–0.646)	0.023(0–1.341)	1.032(0.119–8.981)	2.492(0.349–17.814)	24.964(1.529–407.669)	2.082(0.454–9.553)
P value	0.033	0.069	0.977	0.363	0.024	0.345
SDF-1	0(0–0.033)	0.58(0–2604.789)	0(0–0.3)	0.041(0–12.88)	0.689(0.003–182.49)	0.555(0.004–83.375)
P value	0.007	0.574	0.022	0.165	0.896	0.796
EPC	51.402(1.577–1675.792)	0.095(0–343.289)	0.072(0.008–0.621)	0.018(0–5.223)	0.551 (0.065–4.675)	0.516(0.003–78.047)
P value	0.027	0.521	0.017	0.698	0.585	0.97
IFN-γ	114.417(0.231–56589.897)	1.303(0.009–184.549)	0.68(0.246–1.885)	0.088(0.014–0.566)	0.677(0.273–1.68)	0.157(0.03–0.837)
P value	0.134	0.917	0.459	0.011	0.4	0.003

VEGF, vascular endothelial growth factor; sVEGFR, soluble form of VEGF receptors; SDF-1, stromal cell–derived factor-1; bFGF, fibroblast growth factor; PDFG, platelet-derived growth factor; EPCs, endothelial progenitor cells; IFN, interferon; OS, overall survival; PFS, progression-free survival. P values are from 2-sided Wald test in Cox regression. Data are shown as hazard ratios with 95% confidence intervals. Biomarkers significantly correlated with clinical outcomes are shown in bold. N = 18.